Theramex HQ UK Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Theramex HQ UK Limited - overview
Established
1954
Location
London, -, UK
Primary Industry
Pharmaceuticals
About
Theramex HQ UK Limited, based in the UK, operates as a global pharmaceutical company specializing in women's health, providing an array of therapies to address health challenges faced by women throughout their lives. Founded in 1954 and headquartered in London, UK, Theramex HQ UK Limited focuses on women's healthcare solutions. The company has undergone strategic changes to enhance its product offerings in women’s health and operates as a subsidiary within a private equity portfolio. Its latest funding round, a Secondary Buyout of GBP 1,200.
00 mn, was completed in March 2024 with investors including Carlyle Group and PAI Partners. The company has successfully secured a total of GBP 1,200. 00 mn from three deals, with the most recent deal dated March 19, 2024. The current CEO is Robert Stewart.
Theramex specializes in women's health, offering a diverse portfolio including therapies for contraception, menopause management, osteoporosis treatment, and fertility support. The company primarily serves healthcare professionals and patients across Europe, with significant activities in the United Kingdom, Germany, France, and Italy. Their products aim to effectively address unplanned pregnancies, menopausal symptoms, bone strength issues, and infertility challenges through comprehensive information and support. In 2023, Theramex reported a revenue of GBP 187,845,280.
40, with an EBITDA of GBP 67,951,660. 40. The company's revenue model includes transaction-based sales through partnerships with healthcare providers, hospitals, clinics, and pharmacies, focusing on direct sales agreements and supply contracts that facilitate product distribution. Theramex plans to develop and launch new products in the women's health sector, with specific timelines and products to be announced in the future.
The company aims to expand its footprint into additional geographical markets, targeting regions with high demand for women's health solutions. The recent Secondary Buyout funding of GBP 1,200. 00 mn will support these initiatives, including the development of innovative products and expansion strategies. Additionally, in March 2024, CIC Private Debt provided a EUR 1.
26 million senior term loan, further bolstering their financial capacity to implement these growth strategies.
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals
Website
www.theramex.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Theramex HQ UK Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | Theramex HQ UK Limited | - | ||||||||
| Secondary Buyout | Completed | Theramex HQ UK Limited | - | ||||||||
| Buyout | Completed | Theramex HQ UK Limited | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.